Investor Relations

Investor Relations

Corporate Profile

Dystrogen Therapeutics is a clinical-stage life sciences company committed to developing personalized therapies for rare genetic diseases. The company has two technology platforms, which focus on treating patients with rare diseases such as Duchenne muscular dystrophy, sickle cell anemia, and neurodegenerative disorders such as Huntington’s disease.
The company was founded based on the pioneering work on chimeric cells therapy for transplantation tolerance, developed by Professor Maria Siemionow MD, PhD, a world renowned scientist and surgeon who led a team of surgeons that performed the first near-total face transplantation in the United States. Our technologies are developed in collaboration with the University of Illinois at Chicago and the Institute of Bioorganic Chemistry, Polish Academy of Sciences in Poland.